SENATE BILL NO. 486
AMENDMENT IN THE NATURE OF A SUBSTITUTE
(Proposed by the Senate Committee on Finance and Appropriations
on February 4, 2026)
(Patron Prior to Substitute—Senator Stuart)

A BILL to amend the Code of Virginia by adding sections numbered 3.2-5124.1 and 54.1-3319.1, relating to required disclosures for dietary supplements and medication; gluten disclaimer.

Be it enacted by the General Assembly of Virginia:

1. That the Code of Virginia is amended by adding sections numbered 3.2-5124.1 and 54.1-3319.1 as follows:

§ 3.2-5124.1. Dietary supplements; ingredient disclosure; gluten disclaimer.

A. For purposes of this section:

"Active ingredient" means any dietary ingredient intended to provide nutritional or physiological effect.

"Dietary supplement" means a product intended to supplement the diet that contains one or more dietary ingredients, including vitamins, herbs or other botanicals, amino acids, or other substances, and that is intended for ingestion in tablet, capsule, powder, or liquid form.

"Inactive ingredient" means any component of a dietary supplement other than an active ingredient, including excipients, fillers, binders, flavorings, colorings, preservatives, coatings, or processing aids.

B. No person shall manufacture, distribute, sell, or offer for sale in the Commonwealth a dietary supplement unless the product contains a clear, legible, and conspicuous label listing all active ingredients and inactive ingredients contained in the product.

C. No person shall manufacture, distribute, sell, or offer for sale in the Commonwealth a dietary supplement that contains gluten unless the product contains a clear, legible, and conspicuous disclaimer separate from the list of active ingredients and inactive ingredients that states "contains gluten."

§ 54.1-3319.1. Provision of federally required drug information.

A. When dispensing a prescription drug to a patient, a pharmacist shall provide all information required by federal law to accompany such drug, including the medication guide, patient package insert, or other written patient information.

B. When dispensing a nonprescription drug directly to a patient, a pharmacist shall, upon request, provide counseling consistent with the labeling required under federal law.

C. Nothing in this section shall be construed to require any labeling or disclosure for a drug that is different from or in addition to what is required under federal law.

2. That the provisions of the first enactment of this act shall become effective on July 1, 2027.

3. That the Department of Agriculture and Consumer Services shall estimate the expected and potential costs associated with the implementation and administration of the provisions of the first enactment of this act. The Commissioner of Agriculture and Consumer Services shall submit a report on (i) such cost estimates, (ii) any legislative or regulatory recommendations related to the implementation and administration of the first enactment of this act, and (iii) any other recommendations related to the implementation and administration of the first enactment of this act to the Governor and the General Assembly no later than November 1, 2026.